Literature DB >> 16488373

GDNF in treatment of Parkinson's disease: response to editorial.

Anthony E Lang, J William Langston, A Jon Stoessl, Matthew Brodsky, David J Brooks, Vijay Dhawan, William J Elias, Andres M Lozano, Elena Moro, John G Nutt, Mark Stacy, Dennis Turner, G Frederick Wooten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16488373     DOI： 10.1016/S1474-4422(06)70359-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  7 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Do subjects with minimal motor features have prodromal Parkinson disease?

Authors:  Yaping Chu; Aron S Buchman; C Warren Olanow; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

Review 3.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

4.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

5.  Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson's Disease. A Systematic Review.

Authors:  Piniel Alphayo Kambey; Kouminin Kanwore; Abiola Abdulrahman Ayanlaja; Iqra Nadeem; YinZhen Du; Wokuheleza Buberwa; WenYa Liu; Dianshuai Gao
Journal:  Front Aging Neurosci       Date:  2021-02-24       Impact factor: 5.750

6.  Clearance and toxicity of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHu GDNF) following acute convection-enhanced delivery into the striatum.

Authors:  Hannah Taylor; Neil Barua; Alison Bienemann; Marcella Wyatt; Emma Castrique; Rebecca Foster; Matthias Luz; Christian Fibiger; Erich Mohr; Steven Gill
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

7.  Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz; Howard J Federoff
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.